drugset / Trial / NCT06057025
Study of "Sputnik Lite" for the Prevention of COVID-19 With Altered Antigenic Composition.
Phase 3
Unknown
50 enrolled
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
NaSingle-groupOpen-labelPrevention
Summary
Safety, reactogenicity and immunogenicity study of the drug "Sputnik Lite" for the prevention of coronavirus infection caused by the SARS-CoV-2 virus with altered antigenic composition with participation of adult volunteers.
Timeline
- Start
- 2023-09
- Primary completion
- 2024-12
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sputnik Lite | Unknown | — | Intramuscular |